keyword
MENU ▼
Read by QxMD icon Read
search

interim Pet hodgkin

keyword
https://www.readbyqxmd.com/read/28898338/-response-to-abvd-chemotherapeutic-protocol-in-patients-with-early-stage-hodgkin%C3%A2-s-lymphoma
#1
Javier Díaz, Katherine Soto, Daniel Ernst
BACKGROUND: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. AIM: To report the experience in the treatment of ESHL. MATERIAL AND METHODS: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015...
May 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28867113/precision-medicine-and-pet-computed-tomography-in-pediatric-malignancies
#2
REVIEW
Yasemin Sanli, Ebru Yilmaz, Rathan M Subramaniam
Fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET-computed tomography (CT) plays a significant role in diagnosis, staging, therapy selection, and therapy assessment of multiple pediatric malignancies and facilitating precision medicine delivery in pediatric patients. In patients with Hodgkin lymphoma, interim fludeoxyglucose (18)F-FDG PET/CT is highly sensitive and specific for predicting survival and multiple trials with FDG PET/CT-based adaptive therapies are currently ongoing. It is superior to iodine-131 metaiodobenzylguanidine ((131)I-MIBG) scintigraphy and bone scintigraphy for detecting metastases in neuroblastoma patients and sarcoma patients...
October 2017: PET Clinics
https://www.readbyqxmd.com/read/28864629/predictive-value-of-pet-response-combined-with-baseline-metabolic-tumor-volume-in-peripheral-t-cell-lymphoma-patients
#3
Anne-Segolene Cottereau, Tarec C El-Galaly, Stéphanie Becker, Florence Broussais, Lars Jelstrup Peterson, Christophe Bonnet, John O Prior, Herve Tilly, Martin Hutchings, Olivier Casasnovas, Michel A Meignan
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET)...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28832956/early-stage-hodgkin-lymphoma-outcomes-after-combined-modality-therapy-according-to-the-post-chemotherapy-5-point-score-can-residual-pet-positive-disease-be-cured-with-radiotherapy-alone
#4
Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, Yasuhiro Oki, Mani Akhtari, Osama Mawlawi, Naveen Garg, Jillian R Gunther, Jay P Reddy, Grace L Smith, Eric Rohren, Frederick B Hagemeister, Hun J Lee, Luis E Fayad, Wenli Dong, Eleanor M Osborne, Zeinab Abou Yehia, Michelle Fanale, Bouthaina S Dabaja
Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone...
August 18, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28768246/interim-pet-ct-may-predict-pfs-and-os-in-t-all-lbl-adult-patients
#5
Liang Wang, Jing-Hua Wang, Xi-Wen Bi, Xiao-Qin Chen, Yue Lu, Zhong-Jun Xia
T lymphoblastic leukemia/lymphoma (T-ALL/LBL) is highly aggressive. Although intensive chemotherapies such as ALL-type regimens are commonly used, about half adult patients eventually relapse and die of T-ALL/LBL. Overwhelming evidences have confirmed that interim PET can predict survival outcomes and guide subsequent treatments in Hodgkin lymphoma. However, whether interim PET-CT can predict survival outcomes or not in T-ALL/LBL patients remains unclear. 47 adult patients of T-ALL/LBL were retrospectively reviewed...
July 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28760308/real-life-experience-for-integration-of-pet-ct-in%C3%A2-the-treatment-of-hodgkin-lymphoma-in%C3%A2-lebanon
#6
Riwa Sakr, Marcel Massoud, Fouad Kerbage, Layale Rached, Jean Zeghondy, Elie Akoury, Fady Nasr, Georges Chahine
BACKGROUND: Hodgkin lymphoma (HL) is a highly curable disease; < 80% of patients will achieve long-term survival. Positron emission tomography-computed tomography (PET-CT) has played a major role in the evaluation of both disease staging and response and has become an essential component in tailoring patients' treatment. We report the effect of integrating PET-CT into the management of HL in Lebanon. PATIENTS AND METHODS: We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the end of treatment...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28750493/concomitant-semi-quantitative-and-visual-analysis-improves-the-predictive-value-on-treatment-outcome-of-interim-18f-fluorodeoxyglucose-positron-emission-tomography-in-advanced-hodgkin-lymphoma
#7
Alberto Biggi, Fabrizio Bergesio, Stephane Chauvie, Andrea Bianchi, Massimo Menga, Federico Fallanca, Martin Hutchings, Michele Gregianin, Michel Meignan, Andrea Gallamini
BACKGROUND: Qualitative assessment using the Deauville five-point scale (DS) is the gold standard for interim and end-of treatment PET interpretation in lymphoma. In the present study we assessed the reliability and the prognostic value of different semi- quantitative (SQ) parameters in comparison with DS for interim PET (iPET) interpretation in Hodgkin lymphoma (HL). METHODS: A cohort of 82 out of 260 patients with advanced stage HL enrolled in the International Validation Study (IVS), scored as 3 to 5 by the expert panel was included in the present report...
July 27, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28741053/prediction-of-outcome-in-pediatric-hodgkin-lymphoma-based-on-interpretation-of-18-fdg-pet-ct-according-to-%C3%AE-suvmax-deauville-5-point-scale-and-ihp-criteria
#8
Emine Göknur Isik, Serkan Kuyumcu, Rejin Kebudi, Yasemin Sanli, Zeynep Karakas, Fatma Betul Cakir, Seher Nilgün Unal
OBJECTIVE: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of (18)F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard. METHODS: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria...
July 24, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28711575/how-to-approach-a-patient-with-limited-stage-hodgkin-lymphoma-who-remains-pet-positive-at-the-end-of-chemotherapy-radiation-therapy
#9
REVIEW
Nmazuo W Ozuah, Ann S LaCasce
The use of 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET might even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET-positive after chemotherapy is unknown...
June 29, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28589704/modification-of-initial-therapy-in-early-and-advanced-hodgkin-lymphoma-based-on-interim-pet-ct-is-beneficial-a-prospective-multicentre-trial-of-355-patients
#10
Eldad J Dann, Osnat Bairey, Rachel Bar-Shalom, Tanya Mashiach, Elinor Barzilai, Abraham Kornberg, Luiza Akria, Tamar Tadmor, Kalman Filanovsky, Uri Abadi, Olga Kagna, Rosa Ruchlemer, Roxolyana Abdah-Bortnyak, Neta Goldschmidt, Ron Epelbaum, Netanel A Horowitz, David Lavie, Dina Ben-Yehuda, Ofer Shpilberg, Ora Paltiel
This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission tomography-computed tomography performed after two cycles (PET-2). Between September 2006 and August 2013, 359 patients aged 18-60 years, were recruited in nine Israeli centres. Early-HL patients initially received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) ×2. Depending on initial unfavourable prognostic features, PET-2-positive patients received additional ABVD followed by involved-site radiotherapy (ISRT)...
September 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28570287/usual-and-unusual-pitfalls-of-18f-fdg-pet-ct-in-lymphoma-after-treatment-a-pictorial-review
#11
Julien Dubreuil, Gilles Salles, Juliette Bozzetto, Jeremie Tordo, Loïc Djaïleb, Alina Berriolo-Riedinger, Julien Leenhardt, Francesco Giammarile, Michel Meignan, Andrea Skanjeti
Fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) is now a standard of care in initial staging and treatment evaluation of lymphomas. It is also used in the interim evaluation in diffuse large B cell lymphoma and Hodgkin lymphoma. However, several pitfalls may occur during or after treatment, because of the nonspecificity of F-FDG for lymphoma disease and treatment as immunotherapy, thus possibly induces misinterpretation and wrong treatment decision. The aim of this pictorial review is to provide an illustrated tutorial of the most frequent pitfalls found on F-FDG-PET/CT during or after treatment...
July 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28513853/association-between-textural-and-morphological-tumor-indices-on-baseline-pet-ct-and-early-metabolic-response-on-interim-pet-ct-in-bulky-malignant-lymphomas
#12
Fayçal Ben Bouallègue, Yassine Al Tabaa, Marilyne Kafrouni, Guillaume Cartron, Fabien Vauchot, Denis Mariano-Goulart
PURPOSE: We investigated whether metabolic, textural, and morphological tumoral indices evaluated on baseline PET-CT were predictive of early metabolic response on interim PET-CT in a cohort of patients with bulky Hodgkin and non-Hodgkin malignant lymphomas. METHODS: This retrospective study included 57 patients referred for initial PET-CT examination. In-house dedicated software was used to delineate tumor contours using a fixed 30% threshold of SUV max and then to compute tumoral metabolic parameters (SUV max, mean, peak, standard deviation, skewness and kurtosis, metabolic tumoral volume (MTV), total lesion glycolysis, and area under the curve of the cumulative histogram), textural parameters (Moran's and Geary's indices, energy, entropy, contrast, correlation derived from the gray-level co-occurrence matrix, area under the curve of the power spectral density, auto-correlation distance, and granularity), and shape parameters (surface, asphericity, convexity, surfacic extension, and 2D and 3D fractal dimensions)...
May 17, 2017: Medical Physics
https://www.readbyqxmd.com/read/28483373/optimisation-of-metabolic-criteria-in-the-prognostic-assessment-in-patients-with-lymphoma-a-multicentre-study
#13
M Del Puig Cózar-Santiago, J R García-Garzón, M Moragas-Freixa, M Soler-Peter, P Bassa Massanas, M Sánchez-Delgado, R Sanchez-Jurado, J E Aguilar-Barrios, R Sanz-Llorens, J Ferrer-Rebolleda
OBJECTIVE: To compare sensitivity, specificity and predictive value of Deauville score (DS) vs. ΔSUVmax in interim-treatment PET (iPET) and end-treatment PET (ePET), in patients with diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and follicular lymphoma (FL). METHOD: Retrospective longitudinal multicentre study including 138 patients (46 DLBCL, 46 HL, 46 FL), on whom 3 (18)F-FDG PET/CT were performed: baseline, iPET, and ePET. Visual (DS) and semi-quantitative (ΔSUVmax) parameters were determined for iPET and ePET...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28411336/fdg-pet-for-therapy-monitoring-in-hodgkin-and-non-hodgkin-lymphomas
#14
REVIEW
Sally F Barrington, Regine Kluge
PET using (18)F-FDG for treatment monitoring in patients with lymphoma is one of the most well-developed clinical applications. PET/CT is nowadays used during treatment to assess chemosensitivity, with response-adapted therapy given according to 'interim' PET in clinical practice to adults and children with Hodgkin lymphoma. PET is also used to assess remission from disease and to predict prognosis in the pretransplant setting. Mature data have been reported for the common subtypes of aggressive B-cell lymphomas, with more recent data also supporting the use of PET for response assessment in T-cell lymphomas...
August 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28254870/interim-pet-in-hodgkin-lymphoma-is-it-so-useless
#15
Michel A Meignan, Anne-Segolene Cottereau, Benedicte Deau, Salim Kanoun, Alina Berriolo Riedinger, Olivier Casasnovas
No abstract text is available yet for this article.
March 2, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28237632/predicting-outcomes-after-a-positive-interim-fdg-pet-scan-in-advanced-hodgkin-s-lymphoma
#16
Michael Crump
No abstract text is available yet for this article.
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28236583/progression-free-survival-of-early-interim-pet-positive-patients-with-advanced-stage-hodgkin-s-lymphoma-treated-with-beacoppescalated-alone-or-in-combination-with-rituximab-hd18-an-open-label-international-randomised-phase-3-study-by-the-german-hodgkin-study
#17
RANDOMIZED CONTROLLED TRIAL
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, Ulrich Mey, Stefanie Kreissl, Richard Greil, Jana Markova, Michaela Feuring-Buske, Julia Meissner, Ulrich Dührsen, Helmut Ostermann, Ulrich Keller, Georg Maschmeyer, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Hans Eich, Christian Baues, Harald Stein, Michael Fuchs, Volker Diehl, Andreas Engert
BACKGROUND: Advanced stage Hodgkin's lymphoma represents a heterogeneous group of patients with different risk profiles. Data suggests that interim PET assessment during chemotherapy is superior to baseline international prognostic scoring in terms of predicting long-term treatment outcome in patients with Hodgkin's lymphoma. We therefore hypothesised that early interim PET-imaging after two courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) might be suitable for guiding treatment in patients with advanced stage Hodgkin's lymphoma...
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28185527/use-of-fluorodeoxyglucose-positron-emission-tomography-for-diagnosis-of-bleomycin-induced-pneumonitis-in-hodgkin-lymphoma
#18
Okan Falay, Erman Öztürk, Yasemin Bölükbaşı, Terman Gümüş, Serdar Örnek, Murat Özbalak, Mustafa Çetiner, Onur Demirkol, Burhan Ferhanoğlu
Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity. Early diagnosis of bleomycin-induced pneumonitis is crucial to prevent irreversible damage. Pulmonary function tests are unreliable for identifying risk of bleomycin toxicity. Fluorodeoxyglucose PET/CT scanning can reveal inflammation secondary to pneumonitis but is not sufficiently specific for diagnosis. We retrospectively analyzed scans from 77 patients with Hodgkin lymphoma (median age 41 years, mean bleomycin dose 134 mg) to evaluate bleomycin-induced pneumonitis...
May 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28151888/pediatric-hodgkin-lymphoma-predictive-value-of-interim-18f-fdg-pet-ct-in-therapy-response-assessment
#19
Cristina Ferrari, Artor Niccoli Asabella, Nunzio Merenda, Corinna Altini, Margherita Fanelli, Paola Muggeo, Francesco De Leonardis, Teresa Perillo, Nicola Santoro, Giuseppe Rubini
We investigated the prognostic value of interim F-FDG PET/CT (PET-2) in pediatric Hodgkin lymphoma (pHL), evaluating both visual and semiquantitative analysis.Thirty pHL patients (age ≤16) underwent serial F-FDG PET/CT: at baseline (PET-0), after 2 cycles of chemotherapy (PET-2) and at the end of first-line chemotherapy (PET-T). PET response assessment was carried out visually according to the Deauville Score (DS), as well as semiquantitatively by using the semiquantitative parameters reduction from PET-0 to PET-2 (ΔΣSUVmax0-2, ΔΣSUVmean0-2)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28132716/-18-f-fdg-pet-mri-in-lymphoma-patients
#20
Eva Ferdová, Jiří Ferda, Jan Baxa
The introduction of hybrid PET/MRI imaging using integrated systems into clinical practice has opened up the possibility of reducing the radiation dose from hybrid imaging by eliminating the contribution from computed tomography. Studies comparing the possibilities of PET/CT and PET/MRI imaging demonstrated it is possible to use the advantages of the high contrast resolution of magnetic resonance for soft tissue and bone marrow along with PET records in a quality comparable to PET/CT imaging. The significant feature for PET imaging in Hodgkińs lymphoma is that it is a tissue with high levels of radiopharmaceutical accumulation, which decreases proportionally after successful therapeutic effect, the effect of therapy is assessed using Deauville score system on interim examinations...
January 23, 2017: European Journal of Radiology
keyword
keyword
118763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"